CA2269681A1 - Methode de traitement de la sclerose en plaques - Google Patents

Methode de traitement de la sclerose en plaques Download PDF

Info

Publication number
CA2269681A1
CA2269681A1 CA002269681A CA2269681A CA2269681A1 CA 2269681 A1 CA2269681 A1 CA 2269681A1 CA 002269681 A CA002269681 A CA 002269681A CA 2269681 A CA2269681 A CA 2269681A CA 2269681 A1 CA2269681 A1 CA 2269681A1
Authority
CA
Canada
Prior art keywords
amino
pyrimidinol
bromo
iodo
chloro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002269681A
Other languages
English (en)
Inventor
Francis A. Fitzpatrick
Stephen E. Buxser
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmacia and Upjohn Co LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2269681A1 publication Critical patent/CA2269681A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preliminary Treatment Of Fibers (AREA)
  • Spinning Or Twisting Of Yarns (AREA)
  • Treatment Of Fiber Materials (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

L'invention concerne une méthode de traitement de la sclérose en plaques par administration systémique à un humain présentant des symptômes de sclérose en plaques, d'un composé de 6-aryl pyrimidine ou d'un sel de ce dernier acceptable du point de vue pharmaceutique, associé à un excipient pharmaceutique.
CA002269681A 1996-12-12 1997-12-03 Methode de traitement de la sclerose en plaques Abandoned CA2269681A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3264896P 1996-12-12 1996-12-12
US60/032,648 1996-12-12
PCT/US1997/021402 WO1998025596A2 (fr) 1996-12-12 1997-12-03 Methode de traitement de la sclerose en plaques

Publications (1)

Publication Number Publication Date
CA2269681A1 true CA2269681A1 (fr) 1998-06-18

Family

ID=21866063

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002269681A Abandoned CA2269681A1 (fr) 1996-12-12 1997-12-03 Methode de traitement de la sclerose en plaques

Country Status (5)

Country Link
EP (1) EP0948331A2 (fr)
JP (1) JP2001505911A (fr)
AU (1) AU5687198A (fr)
CA (1) CA2269681A1 (fr)
WO (1) WO1998025596A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6495558B1 (en) 1999-01-22 2002-12-17 Amgen Inc. Kinase inhibitors
EP1144390A2 (fr) * 1999-01-22 2001-10-17 Amgen Inc., Inhibiteurs de kinase
WO2001068613A1 (fr) * 2000-03-17 2001-09-20 Nissan Chemical Industries, Ltd. Dérivés pyrimidinone et herbicides

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5434157A (en) * 1979-03-19 1995-07-18 The Upjohn Company 6-aryl pyrimidine compounds and method for treating viral infections and inducing interferon production
DE3008693A1 (de) * 1979-03-19 1980-10-02 Upjohn Co 6-aryl-pyrimidinverbindungen
AU7798994A (en) * 1993-10-20 1995-05-08 Upjohn Company, The Pyrimidinones as antiarthritic and anti-inflammatories

Also Published As

Publication number Publication date
WO1998025596A3 (fr) 1998-08-13
EP0948331A2 (fr) 1999-10-13
WO1998025596A2 (fr) 1998-06-18
JP2001505911A (ja) 2001-05-08
AU5687198A (en) 1998-07-03

Similar Documents

Publication Publication Date Title
EP1484059B1 (fr) Composées antivirales contenant derivées de l'acide phénylacetique
EP0468520A2 (fr) Remèdes immunostimulants contenant des séquences d'ADN palindromique
CA2427194A1 (fr) Procede pour une dosimetrie de medicaments a court et a long terme
EP1957082A1 (fr) Utilisation de doses elevees de medicaments comprenant de l'oxazaphosphorine pour le traitement de troubles immunitaires
WO2002100429A1 (fr) Polytherapies a base de vitamine b12 et d'interferon destinees au traitement des affections virales, proliferantes et inflammatoires
US5716959A (en) Method of treating disease with piperazine zwitterion compounds
STRINGFELLOW et al. Interferon induction by 5-halo-6-phenyl pyrimidinones
JP3496937B2 (ja) コンセンサスヒトインターフェロンを含有する細胞増殖障害治療用の医用組成物
RU2730998C2 (ru) Композиции форболовых эфиров и способы их применения для лечения или уменьшения продолжительности цитопении
CA2269681A1 (fr) Methode de traitement de la sclerose en plaques
WO2002085916A1 (fr) 9-[(5-dihydroxyboryl)-pentyl]purines, inhibiteur de cytokines inflammatoires
JP2610621B2 (ja) １５―デオキシスペルグアリン含有薬剤
AU2002336864A1 (en) Pharmaceutical compositions for the treatment of leukemia comprising dioxolane nucleosides analogs
Lefkowitz et al. Cocaine reduces macrophage killing by inhibiting reactive nitrogen intermediates
US5264208A (en) Potentiation of tumor necrosis factor (TNF) of interferon B1 (IFN-B1) antiviral activities by an anti-cachexia agent
EP0859630B1 (fr) Combinaison de temozolomide et d'interferon alpha pour le traitement du cancer avance
US5059418A (en) Synergistic effect of human recombinant interferon-beta on halogenated pyrimidines
CN115645385B (zh) 甘草查尔酮b在制备治疗和/或预防ⅰ型干扰素病药物中的应用
EP1250147B1 (fr) Utilisation de l'interferon-alpha dans le traitement le traitement du sarcome de ewing
Cerruti et al. Synergistic interaction between interferon-α and acyclovir in the treatment of herpes simplex virus type 1 infection in mice
JP2003137784A (ja) インターフェロンγ産生促進剤
RU2003334C1 (ru) Способ лечени больных с опухол ми
CN115737617A (zh) 鼠尾草酸或其衍生物在制备治疗和/或预防ⅰ型干扰素病药物中的应用
CN116157126A (zh) 固有免疫激活药物及其用途
US4950470A (en) Methods and compositions employing interferon-gamma

Legal Events

Date Code Title Description
FZDE Discontinued